Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs

International Journal of Pharmaceutics

Volumn 325, Issue 1-2, 2006, Pages 116-123

  Chu, Da Feng ^a,b   Fu, Xue Qi ^b   Liu, Wan Hui ^a,c   Liu, Ke ^a,c   Li, You Xin ^a,b  

^a YANTAI UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c Luye Pharma Group Ltd   (China)

Author keywords

Huperzine A; In vitro in vivo correlation; Microspheres; Pharmacokinetics; Poly(lactic co glycolic acid)

Indexed keywords

HUPERZINE A; MICROSPHERE; POLYGLACTIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CORRELATIONAL STUDY; DOG; DRUG RELEASE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, LIQUID; DOGS; DRUG COMPOUNDING; FEMALE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MALE; MASS SPECTROMETRY; MICROSPHERES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; SESQUITERPENES;

EID: 33750017278     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.06.032     Document Type: Article

References (41)

1. FDA. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In vitro/In vivo Correlations (1997)
2. FDA. Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers (2002)
3. Fu X.D., Gao Y.L., Ping Q.N., and Ren T. Preparation and in vivo evaluation of huperzine A-loaded PLGA microspheres. Arch. Pharm. Res. 28 (2005) 1092-1096
4. Furr B.J.A., and Hutchinson F.G. A biodegradable delivery system for peptides: preclinical experience with the gonadotrophinereleasing hormone agonist Zoladex. J. Contr. Release 21 (1992) 117-128
5. Gao P., Ding P.T., Xu H., Yuan Z.T., Chen D.W., Wei J., and Chen D. In vitro and in vivo characterization of huperzine A loaded microspheres made from end-group uncapped poly(d,l-lactide acid) and poly(d,l-lactide-co-glycolide acid). Chem. Pharm. Bull. (Tokyo) 54 (2006) 89-93
6. Gogolewski S., Jovanovic M., Perren S., Dillon J., and Hughes M. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J. Biomed. Mater. Res. 27 (1993) 1135-1148
7. Huffman K.R., and Casey D.J. Effect of carboxyl end groups on hydrolysis of polyglycolic acid. J. Polym. Sci. Polym. Chem. Ed. 23 (1985) 1939-1954
8. Hwang S.S., Bayne W., and Theeuwes F. In vivo evaluation of controlled-release products. J. Pharm. Sci. 11 (1993) 1145-1150
9. Jiang G., Qiu W., and DeLuca P.P. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres. Pharm. Res. 20 (2003) 452-459
10. Jiang Y.B., Huang C.S., and Huang L.A. Improvement in cognition ability and action drawback of Alzheimer's disease treated by huperzine A. Clin. Med. China 18 (2002) 802-803
11. Liang W.Q. Biopharmaceutics and Pharmacokinetics (2004), People's Medical Publishing House, Beijing pp. 58-88
12. Loo J.C.K., and Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J. Pharm. Sci. 57 (1968) 918-928
13. Machida Y., Onishi H., Kurita A., Hata H., Morikawa A., and Machida Y. Pharmacokinetics of prolonged-release of CPT-11-loaded microspheres in rats. J. Contr. Release 66 (2000) 159-175
14. Negrin C.M., Delgado A., Llabres M., and Evora C. In vivo-in vitro study of biodegradable methadone delivery systems. Biomaterials 22 (2001) 563-570
15. Ranheim B., Ween H., Egeli A.K., Hormazabal V., Yndestad M., and Soli N.E. Benzathine penicillin G and procaine penicillin G in piglets: comparison of intramuscular and subcutaneous injection. Vet. Res. Commun. 26 (2002) 459-465
16. Sandor M., Harris J., and Mathiowitz E. A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. Biomaterials 23 (2002) 4413-4423
17. Schliecker G., Schmidt C., Fuchs S., Ehinger A., Sandow J., and Kissel T. In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis. J. Contr. Release 94 (2004) 25-37
18. Shah S., Cha Y., and Pitt C. Poly(glycolic acid-co-dl-lactic acid): diffusion or degradation controlled drug delivery?. J. Contr. Release 18 (1992) 261-270
19. Soriano I., Evora C., and Llabrés M. Preparation and evaluation of insulin-loaded poly(dl-lactide) microspheres using an experimental design. Int. J. Pharm. 142 (1996) 135-142
20. Spenlehauer G., Vert M., Benoit J.P., and Boddaert A. In vitro and in vivo degradation of poly(d,l-lactide/glycolide) type microspheres made by solvent evaporation method. Biomaterials 10 (1989) 557-563
21. Sun Q.Q., Xu S.S., Pan J.L., Guo H.M., and Cao W.Q. Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Acta Pharmacol. Sin. 20 (1999) 601-603
22. Tang X.C., and Han Y.F. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Rev. 5 (1999) 281-300
23. Tassi P., Ormas P., Madonna M., Carli S., Belloli C., De Natale G., Ceci L., and Marcotrigiano G.O. Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog. Res. Vet. Sci. 56 (1994) 144-150
24. Tracy M., Ward K.L., Firouzabadian L., Wang Y., Dong N., Qian R., and Zhang Y. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20 (1999) 1057-1062
25. Uppoor V. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J. Contr. Release 72 (2001) 127-132
26. Vaag A., Handberg A., Lauritzen M., Henriksen J.E., Pedersen K.D., and Beck-Nielsen H. Variation in absorption of NPH insulin due to intramuscular injection. Diab. Care 13 (1990) 74-76
27. 14C-methylated lysozyme release from poly(ether-ester) microspheres. Pharm. Res. 21 (2004) 484-491
28. Wagner J.G., and Nelson E. Percent absorbed time plots derived from blood level and/or urinary excretion data. J. Pharm. Sci. 52 (1963) 610-611
29. Wang R., Zhang H.Y., and Tang X.C. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur. J. Pharmacol. 421 (2001) 149-156
30. Wang Y.W., Chu D.F., Gu J.K., Fawcett J.P., Wu Y., and Liu W.H. Liquid chromatographic-tandem mass spectrometric method for the quantitation of huperzine A in dog plasma. J. Chromatogr. B 803 (2004) 375-378
31. Woo B.H., Kostanski J.W., Gebrekidan S., Dani B.A., Thanoo B.C., and DeLuca P.P. Preparation, characterization and in vivo evaluation of 120-day poly(d,l-lactide) leuprolide microspheres. J. Contr. Release 75 (2004) 307-315
32. Xiao X.Q., Yang J.W., and Tang X.C. Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci. Lett. 275 (1999) 73-76
33. Xu S.S., Guo Z.X., Weng Z., Du Z.M., Xu W.A., Yang J.S., Zhang M.L., Tong Z.H., Fang Y.S., Chai X.S., and Li S.L. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacol. Sin. 16 (1995) 391-395
34. Xu S.S., Xie H.B., Du Z.M., Tong Z.H., Shi Q.C., Lu K.M., Li S.L., and Li B. Efficacy of tablet huperzine-A on memory and cognition in patients with benign senescent forgetfulness. Chin. J. Clin. Pharmacol. Ther. 2 (1997) 1-4
35. Xu S.S., Cai Z.Y., Qu Z.W., Yang R.M., Cai Y.L., Wang G.Q., Su X.Q., Zhong X.S., Cheng R.Y., Xu W.A., Li J.X., and Feng B. Huperzine-A in capsules and tablets for treating patients with Alzheimer's disease. Acta Pharmacol. Sin. 20 (1999) 486-490
36. Zhang Z., Wang X., Chen Q., Shu L., Wang J., and Shan G. Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind randomized trial. Natl. Med. J. China 82 (2002) 941-944
37. Zhao H.W., and Li X.Y. Ginkgolide A, B, and huperzine A inhibit nitric oxide-induced neurotoxicity. Int. Immunopharmacol. 2 (2002) 1551-1556
38. Zhou J., and Tang X.C. Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett. 526 (2002) 21-25
39. Zhu X.Z., Li X.Y., and Liu J. Recent pharmacological studies on natural products in China. Eur. J. Pharmacol. 500 (2004) 221-230
40. Zuidema J., Pieters F.A.J.M., and Duchateau G.S.M.J.E. Release and absorption rate aspects of intramuscularly injected pharmaceuticals. Int. J. Pharm. 47 (1988) 1-12
41. Zuidema J., Kadir F., Titulaer H.A.C., and Oussoren C. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int. J. Pharm. 105 (1994) 189-207